Last reviewed · How we verify
Ranibizumab injection and TTT - ICG based
Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth in the retina, combined with transpupillary thermotherapy (TTT) using indocyanine green (ICG) guidance for targeted thermal ablation.
Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth in the retina, combined with transpupillary thermotherapy (TTT) using indocyanine green (ICG) guidance for targeted thermal ablation. Used for Wet age-related macular degeneration (AMD), Retinal vein occlusion (RVO), Diabetic macular edema (DME).
At a glance
| Generic name | Ranibizumab injection and TTT - ICG based |
|---|---|
| Also known as | Lucentis injection |
| Sponsor | New England Retina Associates |
| Drug class | VEGF inhibitor (monoclonal antibody fragment) combined with thermal ablation guidance |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Ranibizumab inhibits VEGF-A, a key driver of pathological neovascularization in retinal diseases. The combination with ICG-guided TTT allows real-time visualization of choroidal vasculature during thermal treatment, enabling precise ablation of abnormal vessels while minimizing damage to surrounding healthy tissue. This dual approach targets both the angiogenic stimulus and the structural abnormalities in retinal vascular disease.
Approved indications
- Wet age-related macular degeneration (AMD)
- Retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
Common side effects
- Conjunctival hemorrhage
- Eye pain or discomfort
- Floaters
- Retinal pigment epithelium changes
- Endophthalmitis (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: